Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bristol-Myers Squibb Co's share price for the quarter that ended in Dec. 2023 was $51.15. Bristol-Myers Squibb Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 2,021 Mil. Therefore, Bristol-Myers Squibb Co's market cap for the quarter that ended in Dec. 2023 was $103,374 Mil.
Bristol-Myers Squibb Co's quarterly market cap
declined
from Jun. 2023 ($133,383 Mil) to Sep. 2023 ($118,379 Mil) and
declined
from Sep. 2023 ($118,379 Mil) to Dec. 2023 ($103,374 Mil).
Bristol-Myers Squibb Co's annual market cap
increased
from Dec. 2021 ($134,638 Mil) to Dec. 2022 ($149,286 Mil) but then
declined
from Dec. 2022 ($149,286 Mil) to Dec. 2023 ($103,374 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bristol-Myers Squibb Co's Enterprise Value for Today is $128,211 Mil.
Bristol-Myers Squibb Co Market Cap Historical Data
The historical data trend for Bristol-Myers Squibb Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bristol-Myers Squibb Co's Market Cap
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Market Cap falls into.
Bristol-Myers Squibb Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bristol-Myers Squibb Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (LTS:0R1F) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bristol-Myers Squibb Co Market Cap Related Terms
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Bristol-Myers Squibb Co (LTS:0R1F) Business Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0R1F has been successfully added to your 